{"slug":"ghrp-1","seoKey":"ghrp1","displayName":"GHRP-1","codes":["GHRP-1"],"synonyms":["GHRP 1","GHRP1","growth hormone-releasing peptide 1","GH-releasing peptide 1","GH-releasing heptapeptide","KP 101","KP-101","GHRP-1/AG","Ala-His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2","L-Alanyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamid"],"legalClass":"research_chemical","identifiers":{"cas":"141925-59-9","pubchemCid":10350910,"unii":"39EVI31P0W","inchikey":"NWQWNCILOXTTHF-HLCSKTDOSA-N","chemblId":"CHEMBL427926","wikidataQid":"Q27256893","formula":"C51H62N12O7","molecularWeight":955.1,"sequence":"Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved: three separate negative findings on 2026-09-10. A query of the agency's drug label database returned no records. The alphabetical product listing for the letter G contains no product with this substance; the only growth-hormone-related entries there are somatropin and sermorelin acetate. The substance also appears nowhere on the list of bulk substances for compounding that may present significant safety risks, a page checked with GHRP-2, GHRP-6 and ipamorelin acetate as positive controls, all three of which are listed there in category 2 as of 2023-09-29. The absence therefore means no agency decision has been taken on this substance, most likely because it was never nominated, and not that it has been found safe. Warning letters could not be checked in this session, so none are claimed either way.","date":"2026-09-10","source":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"market":"EU","status":"not_approved","note":"Not approved: no centrally authorised medicinal product. The finding is honest about its limits — the regulator's full-text search returned HTTP 401 from this environment on 2026-09-10 and the medicines overview returned only a search shell without a server-rendered result list. It rests instead on the absence of any registration in every other register checked, on the absence of any trade name across the literature since 1991, and on the absence of an international nonproprietary name.","date":"2026-09-10","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=GHRP-1"},{"market":"DE","status":"not_approved","note":"Not approved on two levels, and the second one is weaker here than for hexarelin. Under medicines law there is neither a centralised nor a national marketing authorisation, so no finished medicinal product containing the substance may be placed on the market. Under anti-doping law the annex to section 2(3) of the anti-doping act carries a collective entry in part II.2.4 for peptides acting like growth hormone releasing factors. Its examples are introduced with the words for example and are therefore not exhaustive: they name GHRP-2 (pralmorelin), GHRP-2-Gly, GHRP-6, GHRP-6-Gly and hexarelin. This substance is not among them. It is caught by the collective clause as a growth hormone releasing peptide, but it is not named in its own right, and that difference is stated rather than blurred.","date":"2026-09-10","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"Not approved: no marketing authorisation known, and unlicensed peptide preparations fall under the general rules for unauthorised medicines in the Human Medicines Regulations 2012. The finding is of limited depth — the regulator's product database returned only a search shell without a server-rendered result list on 2026-09-10, so this is not backed by a register query of its own.","date":"2026-09-10","source":"https://products.mhra.gov.uk/search/?search=GHRP-1"},{"market":"AU","status":"scheduled","date":"2026-05-28","note":"The strictest documented classification of any market, quoted verbatim rather than inferred, but reached through a class entry rather than by name. The Poisons Standard carries the Schedule 4 entry for growth hormone releasing peptides marked with a hash, which points to Appendix D; in the Appendix D table it is item 19, worded to cover those peptides including the ones separately specified in Schedule 4. Clause 5 of that appendix is headed poisons for which possession without authority is illegal, so bare possession without authorisation is unlawful here. Only GHRP-6 (item 20) and pralmorelin, that is GHRP-2 (item 30), are listed separately by name; this substance appears nowhere in the instrument under its own name and is caught by the class entry. No registered finished product is known, though the product register itself timed out on 2026-09-10 and that part is an assessment rather than a register finding.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not approved: the drug product database returned zero records on 2026-09-10, both for the active-ingredient query on growth hormone releasing and for the brand-name query on GHRP. A control query for somatropin in the same run returned several entries, so the interface was working.","date":"2026-09-10","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=growth%20hormone%20releasing"},{"market":"CH","status":"not_approved","note":"Not approved: no marketing authorisation known. The finding is of limited depth — no register could be queried directly in this session on 2026-09-10, so it is an inference from the worldwide absence of any authorisation and of any trade name rather than a register finding of its own. Independently of that, distributing or brokering unauthorised medicinal products is unlawful in this market.","date":"2026-09-10","source":"https://www.swissmedicinfo.ch/"}],"devStage":"discontinued","strongestEvidence":"rct_phase1","wada":{"status":"prohibited","section":"S2.2.4","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT00381602","name":"GHRP-1/AG in Subjects With ESRD on Hemodialysis","phase":"Phase 2","n":3,"status":"TERMINATED"}],"sameAs":["https://www.wikidata.org/wiki/Q27256893","https://pubchem.ncbi.nlm.nih.gov/compound/10350910"],"lastVerified":"2026-09-10","version":"1.0","published":true,"locale":"en","title":"GHRP-1: what the studies show, status and safety","summary":"GHRP-1 is a lab-made peptide of seven building blocks that prompts the pituitary gland to release growth hormone, by docking onto the receptor for the hunger hormone ghrelin. Cyril Bowers and his colleagues described it in the early 1990s, and four small studies gave it to people between 1993 and 2000. All four gave a single dose and measured a hormone level, and no study has ever tested repeated dosing. No country has approved it, the world anti-doping list names it, and two better-known peptides, ipamorelin and NN703, were built from its skeleton.","updated":"2026-09-10","url":"https://mypep.app/peptides/ghrp-1"}